Patent SG-11201810495Y-A (SG)
Title: Method of prognosing and predicting breast cancer recurrence, markers employed therein and kit thereof
Inventor: BAKRE MANJIRI
IPC: G01N33/574
Filed: 2017-05-24
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111111111111111 1111111111010111110010101111101011101110111111111011110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2017/203444 Al 30 November 2017 (30.11.2017) WIPO I PCT (51) International Patent Classification: EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, GO1N 33/574 (2006.01) MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (21) International Application Number: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, PCT/IB2017/053060 KM, ML, MR, NE, SN, TD, TG). (22) International Filing Date: Declarations under Rule 4.17: 24 May 2017 (24.05.2017) — of inventorship (Rule 4.17(iv)) (25) Filing Language: English Published: (26) Publication Language: English — with international search report (Art. 21(3)) (30) Priority Data: 201641017874 24 May 2016 (24.05.2016) IN (71) Applicants: ONCOSTEM DIAGNOSTICS PVT. LTD. [IN/IN]; 4, 2nd Floor, Aanand Towers, Raja Ram Mohan Roy Road, South Wing, Karnataka, Bangalore 560025 (IN). ONCOSTEM DIAGNOSTICS (MAURITIUS) PVT. LTD. [MU/MU]; 4th Floor, Raffles Tower, 19, Cybercity, Republic of Mauritius, Ebene (MU). (72) Inventors: BAKRE, Manjiri; 4, Purva Parkridge, Gosha- la Road, Mahadevpura Post, Karnataka, Bangalore 560048 (IN). RAMKUMAR, Charusheila; Flat 311, Vanshee Solitaire, 4th Main, 1st Cross, Chinnapnahalli, Marthahalli, Karnataka, Bangalore 560037 (IN). (74) Agent: RAVINDRANATH, Meenakshi et al.; K & S Part- ners Intellectual Property Attorneys, 4121/B, 6th Cross, 19A Main, HAL II Stage (Extension), Bangalore, Karnata- ka 560 038 (IN). = (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every = kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 1-1 iv (54) Title: METHOD OF PROGNOSING AND PREDICTING BREAST CANCER RECURRENCE, MARKERS EMPLOYED 71. THEREIN AND KIT THEREOF 71' M (57) : The present disclosure relates to a method of prognosing and predicting breast cancer recurrence in patients. More N particularly, the present disclosure relates to a method of prognosing which stratifies early stage ER+/PR+ and Her2- breast cancer ---. patients with invasive ductal/lobular carcinoma of the breast into low risk or high risk for breast cancer recurrence by employing an IHC IN based assay which assesses or measures expression of a combination of 5 biomarkers and by employing a histopathological analysis 1-1 c;;;;) which assesses 3 clinical prognostic parameters. The present disclosure also relates to a combination of 5 biological markers and 3 ei clinical prognostics markers employed in the method for prognosis of breast cancer, a kit/test comprising the antibodies against said 0 markers for said prognosis and an IHC based assay system comprising said markers.